EUNETWORKS-FIBER-UK-LTD.
21.9.2022 10:01:49 CEST | Business Wire | Press release
euNetworks Fiber UK Limited (“euNetworks”), a Western European bandwidth infrastructure company, has deployed a new ultra low latency route between Basildon and London in the UK that connects the ICE data centre to Interxion LON1 & 2: A Digital Realty Company, and onwards to Slough. These are critical locations for financial markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220921005083/en/
Paula Cogan, President euNetworks (Photo: Business Wire)
The new route is over 45km long and includes 14km of ultra low latency CoreSmart® cable. Lumenisity® Limited (“Lumenisity”) supplied the award-winning CoreSmart cable, which is based on NANF® hollowcore technology to enable transmission over long distances and is compatible with regular single mode fibre – both major constraints on other hollowcore fibre architectures. The route is the longest commercial deployment of hollowcore fibre technology to date and its use is exclusive to euNetworks and its customers. It is also the first commercial construction of a long distance hybrid route of hollowcore fibre and regular single mode fibre.
Offering euNetworks’ dedicated network platform euTrade, at bandwidths between 1G and 10G, this hybrid route is 10% faster than an equivalent all single mode fibre cable. It’s the third deployment for euNetworks following successful deliveries of the first hollowcore fibre based commercial route in April 2021 and the second in March earlier this year.
“We have successfully delivered increasingly longer deployments of hollowcore fibre in our network, becoming the first fibre provider in the world to utilise the benefits of this new fibre technology in commercial markets,” said Paula Cogan, President of euNetworks. “From the initial 1km pilot, the teams have gone on to deploy hollowcore cable lengths of 7km and 14km on our network, as well as successfully blending hollowcore fibre with regular single mode fibre on this latest route. We continue to be focused on delivering the best possible bandwidth solutions for our customers and look forward to deploying longer routes with Lumenisity in the coming quarters. Leading the market in fibre-based ultra low latency services throughout Europe remains a key focus for euNetworks.”
“We are pleased to partner with euNetworks again, successfully deploying this new route and achieving this hollowcore cable link length”, said Tony Pearson, VP Sales & Marketing at Lumenisity. “We are excited to reach this milestone with euNetworks, and will continue to deliver a unique cable solution offering longer reach and lower latency for their customers.”
Data travels 50% faster in hollowcore cable, reducing latency by 33%, and providing a round trip saving of 3μs (three microseconds) per kilometre. These latency savings are hugely significant in financial trading applications. They can also be scaled to increase the separation of data centres by 50%, whilst maintaining the latency envelope, more than doubling the area of land in which these data centres can be located.
euNetworks’ euTrade solution is a dedicated network platform supporting the bandwidth needs of the financial services community. The company continues to optimise routes between all the key trading exchanges in Europe, and is supporting major exchange moves this year. This focus ensures delivery of the shortest paths and lowest latencies available in the market.
About euNetworks
euNetworks is a critical bandwidth infrastructure company, owning and operating 17 fibre based metropolitan networks connected with a high capacity intercity backbone covering 53 cities in 17 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 480 today. euNetworks is also a leading cloud connectivity provider and offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, mobile, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs. For further information visit eunetworks.com.
About Lumenisity® Limited
Lumenisity is an established independent company originally spun out from the world-renowned Optoelectronics Research Centre (ORC) at the University of Southampton. Formed in 2017 to commercialise breakthroughs in the development of hollowcore optical fibre at the ORC, the company has built a team of industry leaders and experts to realise their goal to be the world’s premier high-performance hollowcore fibre optic cable solutions provider offering their customers reliable, deployable, low latency and high bandwidth connections that unlock new capabilities in communication networks. Lumenisity®, NANF® and Coresmart® are registered trademarks of Lumenisity Limited.
Visit our website at: www.lumenisity.com and visit the team on booth 369 at the ECOC 2022 Exhibition in Basel (19th – 21st September) to find out more about our hollowcore cable solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005083/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom